Publicacións en colaboración con investigadores/as de Shanghai Pulmonary Hospital (1)

2023

  1. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

    Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106